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ApoptosisThe ubiquitin proteasome system (UPS) is the main system for controlled protein degradation and a key regula-
tor of fundamental cellular processes. The dependency of cancer cells on a functioning UPS has made this an at-
tractive target for development of drugs that show selectivity for tumor cells. Deubiquitinases (DUBs, ubiquitin
isopeptidases) are components of the UPS that catalyze the removal of ubiquitin moieties from target proteins
or polyubiquitin chains, resulting in altered signaling or changes in protein stability. A number of DUBs regulate
processes associated with cell proliferation and apoptosis, and as such represent candidate targets for cancer
therapeutics. The majority of DUBs are cysteine proteases and are likely to be more “druggable” than E3 ligases.
Cysteine residues in the active sites of DUBs are expected to be reactive to various electrophiles. Various com-
pounds containing α,β-unsaturated ketones have indeed been demonstrated to inhibit cellular DUB activity. In-
hibition of proteasomal cysteine DUB enzymes (i.e. USP14 and UCHL5) can be predicted to be particularly
cytotoxic to cancer cells as it leads to blocking of proteasome function and accumulation of proteasomal sub-
strates. We here provide an overall review of DUBs relevant to cancer and of various small molecules which
have been demonstrated to inhibit DUB activity.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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. This is an open access article undercellularmetabolism. ~30% of newly synthesized proteins inmammalian
cells are rapidly degraded with a half-life of b10 min (Schubert et al.,
2000). Such a high rate of protein turnover requires a specialized system
for the controlled and selective degradation of unwanted proteins. The
ubiquitin–proteasome system (UPS) has emerged as a key regulator of
protein function and stability. At its most simple level the UPS is com-
posed of a tagging factor in the form of the small molecule ubiquitin
which marks unwanted or damaged proteins for degradation, and the
proteasome, a large molecular shredder that breaks down proteins
into smaller peptides for use in other anabolic processes. More than
80% of cellular proteins are degraded by the UPS, high-lighting the im-
portance of this pathway in the regulation of multiple cellular processes
(Rock et al., 1994). The multifaceted role of the UPS includes the degra-
dation of misfolded and damaged proteins, cell cycle regulators, onco-
gene and tumor suppressor proteins, as well as the regulation ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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et al., 1996; Hershko & Ciechanover, 1998). Considering the diversity
of UPS substrates it is no surprise that this pathway has been implicated
in the pathogenesis ofmany human diseases such as neurodegenerative
disorders, viral diseases and cancer (Ciechanover et al., 2000).
The process of ubiquitination is a multi-step process ultimately lead-
ing to the covalentmodiﬁcation of a protein substratewith the smallmol-
ecule ubiquitin. Ubiquitin is a highly conserved 76 amino acid protein
that undergoes covalent attachment via an isopeptide bond between
the carboxy glycine residue (G76) of ubiquitin to the ε-amino groups of
lysine residues in target proteins. The process of ubiquitination is depen-
dent on the consecutive activity of three distinct enzymes, Ub-activating
(E1), Ub-conjugating (E2) and Ub-ligating (E3) (Fig. 1). In the ﬁrst step,
ubiquitin is activated by the E1 enzyme in the presence of ATP, forming
a thioester bond between the carboxy-terminal glycine residue of ubiqui-
tin and the active site cysteine of the E1 enzyme.Once activated, ubiquitin
is transferred from E1 to a cysteine residue of one of the 30–40 E2 ubiq-
uitin carrier proteins. Substrate speciﬁcity is conferred by E3 ligases,
which bind target substrates and co-ordinate the covalent attachment
of ubiquitin. Two distinct families of E3 ligases exist, the HECT domain
family that receives ubiquitin from the E2 ligase forming an ubiquitin-
E3 intermediate, and the RING ﬁnger family of E3 ligases that form amo-
lecular bridge between the E2 ligase and target proteins. There are N500
E3 ligases in cells, making them the main speciﬁcity factor in the UPS
(Hershko et al., 1983; Voges et al., 1999; Pickart & Eddins, 2004).
There are three different classes of ubiquitination: i) mono-
ubiquitination where a single ubiquitin is attached, ii) multi-
ubiquitination or poly-monoubiquitination where several singleE1
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Fig. 1.Ubiquitination of proteins. Proteins are targeted for degradation by the addition of ubiquit
by a ubiquitin-activating enzyme (known as E1) and transferred to a cysteine residue of a ubiq
covalent attachment of ubiquitin. The existence of a large number (N500) of E3 ligases makes
or, as in this example, polyubiquitinated. A target protein must be tagged with at least four ububiquitin moieties are attached, and iii) poly-ubiquitination where
substrates are tagged with polyubiquitin chains (Jentsch &
Schlenker, 1995; Hicke, 2001; Di Fiore et al., 2003; Haglund et al.,
2003; Haglund & Dikic, 2005; Ye & Rape, 2009; Lander et al., 2012).
In addition to the three different classes of ubiquitination, a ubiqui-
tin code exists whereby the type of linkages between ubiquitin
monomers determines function. Ubiquitin contains seven lysine res-
idues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63), any of
which can serve as sites for the covalent attachment of other ubiqui-
tin molecules. The nature of the linkages within the polyubiquitin
chain has consequences in determining the fate of the conjoined
protein. In general, proteins tagged with Lys48-linked polyubiquitin
chains are destined for proteasomal degradation (Chau et al., 1989;
Hershko & Ciechanover, 1998), whereas modiﬁcations involving
Lys63-linked chains are more typically associated with non-
proteasomal roles such as DNA repair, DNA replication and signal
transduction (Haglund & Dikic, 2005). Other linkage types are gen-
erally less well characterized, although reports have shown that
polyubiquitin chains linked through Lys6, Lys11, Lys27, Lys29, or
Lys33 can target proteins for proteasome-mediated degradation
(Xu et al., 2009). Even Lys63 chains, which are more traditionally
implicated in signaling, can target the attached protein to the pro-
teasome for degradation (Saeki et al., 2009).
The process of ubiquitination is highly dynamic and can be reversed
by the action of specialized enzymes known as deubiquitinases (DUBs).
DUBs oppose the action of the E3 ligases by cleaving the isopeptide bond
between lysine residues on target proteins and the C-terminal glycine of
ubiquitin. Analysis of the human genome shows the presence of ~80E2
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in chains to lysine residues by a process that involves three enzymes. Ubiquitin is activated
uitin carrier protein (known as E2). E3 ligases bind target substrates and co-ordinate the
them the main speciﬁcity factor in the UPS. Target proteins may be monoubiquitinated
iquitin monomers (forming a polyubiquitin chain) to be recognized by the proteasome.
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Fig. 2. Structure of the proteasome inhigher eukaryotes. Thevarious components of the20S
core particle (CP) and 19S regulatory particles (RP) are shown. The 20S proteasome con-
tains 14 different subunits overall (α1–α7 and β1–β7) which show molecular masses be-
tween 20 and30 kDa, totalling amolecularweight of ~700 kDa. Theα-rings are responsible
for the regulation of substrate entrance and for recognition and binding of the substrate
whereas the catalytic centers are located in the β-rings. The β1 subunit shows a
peptidyl–glutamyl–peptide hydrolyzing activity (“caspase-like” activity); the β2 subunit
cleaves after basic amino acids (“trypsin-like” activity); theβ5 subunit cleaves after neutral
amino acids (“chymotrypsin-like” activity). The 19S regulatory particle consists of two
main structures: a ring-shaped base and a lid that recognizes and binds polyubiquitinated
proteins. The base ring contains at least 10 different subunits (Rpt1–Rpt6, Rpn1, Rpn2,
Rpn10 and Rpn13). The lid contains 9 subunits (Rpn3, Rpn5–Rpn9, Rpn11, Rpn12 and
Rpn15). The Rpt-subunits display ATPase activity (Rpt: regulatory particle ATPase), Rpn-
subunits do not (Rpn: regulatory particle non-ATPase). Rpn11 (POH1) is a metalloprotease
with DUB activity.
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of the ~460 functional proteases (Fortelny et al., 2014). Based on active
site homology, DUBs can be divided into six classes: ubiquitin-speciﬁc
proteases (USPs), ubiquitin carboxy-terminal hydrolases (UCHs),
ovarian-tumor proteases (OTUs), Machado–Joseph disease protein do-
main proteases, JAMM/MPN domain-associated metallopeptidases
(JAMMs) and monocyte chemotactic protein-induced protein (MCPIP)
(Fraile et al., 2012; Fortelny et al., 2014). Of these DUBs, the USP class
is the most numerous, due to a rapid diversiﬁcation during evolution,
possibly in concert with the diversiﬁcation of E3 ligases (Semple et al.,
2003). This process has presumably led to an increased capacity for
speciﬁc ubiquitination and deubiquitination events, similar to that ob-
served for protein phosphorylation, where both kinases and phospha-
tases are important for regulatory circuits. A more detailed overview
of different DUBs is given below.
2. The proteasome
The 26S proteasome is a large ATP-dependent protease complex
found in the cytosol and the nucleus of eukaryotic cells (Tanaka et al.,
1983; Bochtler et al., 1999; Goldberg, 2003). The 26S proteasome con-
sists of ~50 different subunits with a combined molecular weight of
~2.5 MDa (Fig. 2). The 26S proteasome is arranged into two sub-
complexes: a catalytic 20S core particle (CP) capped by one or two
19S regulatory particle(s) (19S RP).
2.1. The 20S core particle
The eukaryotic 20S CP is a ~730 kDa cylinder-shaped multimeric
complex composed of two heptameric inner β-rings capped by two
heptameric α-subunits (Groll et al., 1997; Unno et al., 2002). The
outerα-rings provide attachment sites for the 19S RP aswell as forming
a 13 Å molecular gate to control substrate access to the catalytic cham-
ber. The proteolytic activity of the 20S CP is mediated by the β1, β2 and
β5 subunits, which contain catalytically active threonine residues at
their N termini. The catalytic β-subunits are classiﬁed based on sub-
strate preference with the β1-subunits associated with caspase-like ac-
tivity, β2-subunits with trypsin-like activity, and β5-subunits with
chymotrypsin-like activity. Substrate proteins are degraded into
oligopeptides ranging in length from 3 to 15 amino-acid residues,
which are subsequently hydrolyzed by cytosolic peptidases into free
amino acids (Puhler et al., 1992; Zwickl et al., 1992; Lowe et al., 1995;
Groll et al., 1997). Alternatively, proteasome-processed oligopeptides
may be taken up by the TAP1 complex and loaded onto histocompatibil-
ity complex (MHC) class I molecules for presentation to the immune
system (Saeki & Tanaka, 2012).
2.2. The 19S regulatory particle
The 19S RP is a ~930 kDa complex consisting of at least 19 different
subunits that can be further divided into lid and base sub-complexes
(Glickman et al., 1998; Lander et al., 2012) (Fig. 2). The base of the 19S
RP is composed of ten subunits, six of which are related AAA+ ATPases
(Rpt1–Rpt6) that form a hetero-hexameric ring (Tomko et al., 2010).
The ATPase ring plays an important role in the opening of the gated
channel to the 20S CP as well as utilizing the hydrolysis of ATP to drive
the unwinding and translocation of ubiquitinated proteins through the
narrow pore into the 20S CP for degradation (Smith et al., 2007; Martin
et al., 2008; Rabl et al., 2008; Zhang et al., 2009; Maillard et al., 2011;
Erales et al., 2012). The other four base subunits are the scaffolding pro-
teins Rpn1 and Rpn2 and the ubiquitin receptors S5a/Rpn10 and Rpn13.
These receptors display preferences for the type of ubiquitin complexes
captured. Rpn10 contains two C-terminal ubiquitin-interacting motifs
(UIMs) that cooperate to bind polyubiquitin chains (Deveraux et al.,
1995; Elsasser et al., 2004; Finley, 2009), whereas, Rpn13 binds to
Lys48-linked di-ubiquitin with high afﬁnity. In addition, three non-constitutive ubiquitin receptors, Rad23, Dsk2 and Ddi1, also associate
with the proteasome and modulate the binding of ubiquitinated cargo.
The extrinsic ubiquitin receptors contain ubiquitin-like (UBL) domains
that bind to the 19S RP subunits Rpn1, Rpn10 and Rpn13 and
ubiquitin-associated (UBA) domain that bind polyubiquitinated sub-
strates (Hartmann-Petersen & Gordon, 2004). In addition to binding
ubiquitin, Rpn13 serves also as a receptor for the DUBs Uch37/UCHL5,
thus providing a link between chain recognition and disassembly
(Husnjak et al., 2008).
In order to facilitate the degradation of proteasome-targeted sub-
strates, specialized proteasome-associated DUBs function to remove
bulky ubiquitin moieties that may otherwise impede entry to the 20S
CP (Verma et al., 2002; Yao & Cohen, 2002). This process also leads to
recycling of free ubiquitin for further use by the UPS (Fig. 3). Such
DUB activity also provides a care taker function by clearing of
substrate-free polyubiquitin chains that may otherwise become stuck
to the proteasome.
Three DUBs are associated with the proteasome: Rpn11/POH1,
Ubp6/USP14 and Uch37/UCHL5 (yeast/human nomenclature). Rpn11/
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and is an integral part of the 19S RP lid. Uch37/UCHL5 and Ubp6/
USP14 are cysteine proteases and members of the ubiquitin C-
terminal hydrolase (UCH) and ubiquitin speciﬁc protease (USP) fami-
lies, respectively. Both UCHL5 and USP14 are physically associated
with the base complex of the 19S RP, and their DUB activity is stimulat-
ed upon proteasome incorporation.
Rpn11/POH1 is essential for viability in yeast and metazoan cells
(Rinaldi et al., 1998; Gallery et al., 2007). In addition to its function as
a DUB, Rpn11/POH1 is essential for 26S proteasome structure and activ-
ity (Lundgren et al., 2003; Gallery et al., 2007). Rpn11/POH1 contains a
JAMM/MPN+ motif sequence containing two histidine residues and an
aspartic residue coordinating a zinc ion, which is important for proteo-
lytic activity (Maytal-Kivity et al., 2002; Ambroggio et al., 2004). The ac-
tivity of Rpn11/POH1 is thought to be delayed until the proteasome is
committed to degrade the substrate (Verma et al., 2002; Yao & Cohen,
2002; Lee et al., 2011). Rpn11/POH1 cleaves the proximal end of the
polyubiquitin chain from the substrate, resulting in the release of a
free ubiquitin chain. To allow cleavagewithout disengaging from the re-
ceptor, an ubiquitin chain must be long enough to span the distance be-
tween the receptor and the DUB. At least four ubiquitin moieties are
necessary to span the distance between receptors Rpn10 or Rpn13
and Rpn11/POH1 (Verma et al., 2002; Yao & Cohen, 2002; Lander
et al., 2012).
TheDUBUSP14 is important for ubiquitin recycling. ThisDUB is not a
constitutive proteasome subunit and reversibly associates with the
Rpn1 subunit of the 19S RP base. Association of USP14 with the protea-
some results in enhanced DUB activity (~1000 fold) when compared to
unbound enzyme (Borodovsky et al., 2001). The USP14 protein contains
an N-terminal 9-kDa UBL domain and a 45-kDa catalytic domain.
Cys114, His435, and Asp451 form a catalytic triad in the active site of
free USP14, and the catalytic mechanism of USP14 appears to parallel
that of the papain family of cysteine proteases (Hu et al., 2005). USP14
is structurally related to USP7 (HAUSP). An important difference is
that the catalytic site is misaligned in free USP7 and is properly formed
after binding of ubiquitin (Hu et al., 2005). The ubiquitin binding pocket
of Ubp6/USP14 is blocked by two loopswhichmust be removed in order
to catalyze deubiquitination (Hu et al., 2005). It has been proposed that
the binding of Ubp6/USP14 to the base of the 19S RP induces a confor-
mational change in the two loops to make the active site for ubiquitin
accessible (Hu et al., 2005). Lys48-linked polyubiquitin chains are the
preferable substrates for Ubp6/USP14 and are cleaved from their distal
tips (Hu et al., 2005; Hanna et al., 2006).
Ubp6/USP14 was shown to inhibit proteasome activity by delaying
the breakdown of proteins by the proteasome (Lee et al., 2010, 2011).
It is suggested that Ubp6/USP14 prevents deubiquitination of the pro-
teasome substrate by Rpn11/POH1. This allows the substrate to be
docked at the proteasome for a longer time, thus resulting in more ex-
tensive trimming of ubiquitin chains, which reduces substrate binding
afﬁnity to the proteasome and favors release back to the cytosol
(Hanna et al., 2006; Lee et al., 2010). The Saccaromyces cerevisiae
orthologue of USP14, Ubp6, is nonessential for cell viability (Guterman
& Glickman, 2004), although it appears important for cell survival fol-
lowing metabolic stress. In mammalian cells, knock-down of USP14
had no detectable effect on proteasome structure or the accumulation
of polyubiquitin (Koulich et al., 2008). The small molecule USP14 inhib-
itor IU1was shown to reduce chain trimming and stimulate proteasome
degradation, indicating the ability of USP14 to inhibit the proteasome
through its deubiquitinating activity (Lee et al., 2010). Although non-
essential for cell survival, USP14 does appear to be important for normal
neuronal development. USP14 mutant mice (axJ/axJ mice) develop se-
vere tremors, hindlimb paralysis and die by 6–10 weeks of age
(Wilson et al., 2002). In these mice, the levels of monomeric ubiquitin
are decreased at synapses, suggesting that decreased recycling of ubiq-
uitin at synapses cannot be fully compensated by axonal transport of
newly synthesized ubiquitin (Chen et al., 2009). These differentobservations could be explained by USP14 being required for ubiquitin
turnover in particular cellular compartments.
Ubp6/USP14 is also involved in the regulation of gate opening of the
20S core particle. Binding of polyubiquitin conjugates to the 26S protea-
some increases peptide hydrolysis by increasing 20S gate opening.
Polyubiquitin conjugates interact with Ubp6/USP14 and in this way
stimulate gate opening, enabling the substrate to be degraded (Peth
et al., 2009). Efﬁcient proteolysis is a multistep process and Ubp6/
USP14 is clearly critical in integrating these multiple reactions. While
helping to remove the ubiquitin chain, it also enhances gate opening
by the ATPase ring in order to ensure efﬁcient destruction of the sub-
strate. It has been found that most of the cellular Ubp6/USP14 is not as-
sociated with the proteasome, indicating that it may be involved in
other cellular processes (Koulich et al., 2008).
The Uch37/UCHL5 deubiquitinase is well conserved from fungi to
humans (Yao et al., 2006). An orthologue of human Uch37 has not
been found in S. cerevisiae. The orthologue in Saccaromyces pombe,
Uch2, is nonessential for viability (Li et al., 2000). Uch37/UCHL5 appears
to be reversibly associates with the proteasome (Hamazaki et al., 2006;
Jorgensen et al., 2006; Qiu et al., 2006; Yao et al., 2006). In contrast to
Rpn11/POH1, Uch37/UCHL5 is not important for the activity or the
structure of the 26S proteasome. The isopeptidase enzyme activity of
Uch37/UCHL5 is enhanced after binding of the protein to the 26S pro-
teasome (Koulich et al., 2008) via the Rpn13/Admr1 receptor in the
19S RP base complex. The UCH-domain contains an active-site cross-
over loop which must be displaced to allow substrate entry. This auto-
inhibitory function is reversed by binding of Uch37/UCHL5 to Rpn13/
Admr1 of the proteasome (Hamazaki et al., 2006; Qiu et al., 2006; Yao
et al., 2006). Similar to Ubp6/USP14, Uch37/UCHL5 removes ubiquitin
from the distal tip of polyubiquitin chains. While Ubp6/USP14 is able
to release di- and tri-ubiquitin from chains, Uch37/UCHL5 releases
only monoubiquitin (Lam et al., 1997; Hanna et al., 2006). Uch37/
UCHL5 cleaves both Lys48- and Lys63-linked polyubiquitin chains
(Jacobson et al., 2009). It is believed that Uch37/UCHL5 suppresses pro-
tein degradation by shortening the chains of inappropriately or poorly
modiﬁed substrates (Lam et al., 1997; Koulich et al., 2008). In contrast,
a recent study has suggested that Uch37/UCHL5 promotes the degrada-
tion of speciﬁc proteasome substrates, nitric oxide synthase and IκB-α
(Mazumdar et al., 2010). Thus, Uch37/UCHL5 appears to suppress the
degradation of some substrates while promoting the degradation of
others.
The exact difference in catalytic function between Ubp6/USP14 and
Uch37/UCHL5 is not clear. Double knockdown of Ubp6/USP14 and
Uch37/UCHL5 results in inhibition of cell growth, decreased protein
degradation, and accumulation of polyubiquitinated proteins, a pheno-
type similar to that observed after knock-down of Rpn11/POH1
(Lundgren et al., 2003). RNAi-mediated down-regulation of either
DUB alone creates a complete opposite phenotype where cell growth
is not affected and reduced levels of polyubiquitinated proteins are ob-
served, indicating that each enzyme could compensate for loss of func-
tion of the other (Koulich et al., 2008).
3. DUBs as drug targets for cancer therapeutics
In the following section we will discuss parts of the literature rele-
vant to the role of DUBs in cancer, as well as the therapeutic potential
of targetingDUBs as a treatment option for cancer (see also excellent re-
views by Nijman et al. (2005b), Hussain et al. (2009), Komander et al.
(2009), Sacco et al. (2010), Ramakrishna et al. (2011), and Eletr and
Wilkinson (2014)). Several DUBs have been described to play essential
roles in the regulation of numerous cellular processes, particularly those
frequently altered in tumorigenesis, e.g. cell cycle control, cell signaling
and apoptosis.Wewill brieﬂy describe theseDUBs and give examples of
their roles in the etiology of cancer. Several functional screenshave been
performed to identify DUBs involved in complex processes such as DNA
repair, cell cycle regulation and receptor signaling. These studies have
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Fig. 3. Proteolysis by the proteasome. Polyubiquitinated proteins are recognized and bind to the 19S regulatory particle by an ATP-dependent mechanism. Substrates must be partially
unfolded before they enter into the catalytic chamber of the 20S core particle. Substrate unfolding is an energy-dependent process. The polyubiquitin chain is removed by proteasome-
associated DUBs (deubiquitinases, ubiquitin isopeptidases) prior to translocation of the substrate into the 20S particle. Proteolysis occurs within the central chamber, generally resulting
in ~7–9 amino acid peptides.
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gesting considerable redundancy in DUB-regulated processes.
3.1. Examples of cellular processes involving DUBs
The process of ubiquitination has been shown to play essential roles
for DNA-repair and DNA-damage response pathways. These pathways
typically involve the mono-ubiquitination of key DNA-repair proteins
that have important regulatory functions in processes such as homolo-
gous recombination and trans-lesion DNA synthesis (Huang &
D'Andrea, 2006). One of the most studied DUBs in DNA repair is USP1,
a negative regulator of FANCD2 mono-ubiquitination (Nijman et al.,
2005a). USP1 also deubiquitinates PCNA (proliferating cell nuclear anti-
gen), an important component of the trans-lesions synthesis (TLS) re-
pair pathway (Huang et al., 2006). USP28 is required for the
stabilization of Chk2 and 53BP1 following DNA damage (Zhang et al.,
2006) and loss of USP28 is predicted to increase the susceptibility to
ionizing radiation. The DUB BRCC36 is a constituent of the BRCC
(BRCA1 and BRCA2 Containing Complex) (Dong et al., 2003). This com-
plex is required for the response to ionizing radiation and for maintain-
ing a G2 DNA checkpoint. BRCC36 counteracts the ubiquitination of
H2AX and H2A to terminate the double-strand break response
(Sobhian et al., 2007).
Ubiquitination of H2B leads to amore open chromatin structure, en-
hancing the accessibility for transcription factors and DNA repair pro-
teins. The ubiquitination of H2B is regulated by the E3 ligase action of
the RNF20–RNF40 complex and the opposing activity by a number of
DUBs, including USP7, USP22 and USP44. Many advanced cancers typi-
cally display low levels of ubiquitinated H2B compared to normal orearly stage tumors, suggesting a role for these enzymes in disease pro-
gression. Components of the UPS regulating H2B ubiquitination status
may represent new therapeutic targets for the treatment of cancer
(Cole et al., 2014). Consistent with this concept, compounds that inhibit
the UPS have been shown to act in synergy with clinically used DNA
damaging drugs.
As recently reviewed (Ramakrishna et al., 2011), a number of DUBs
have been shown to regulate the process of programmed cell death (ap-
optosis), either positively or negatively. These authors listed 14 DUBs
with apoptosis promoting activity, including USP7, USP9x, USP28 and
CYLD. Only 3 DUBs were regarded as negative regulators of apoptosis
(A20, USP18 and UCHL3). From a perspective of small molecule inhibi-
tors as cancer therapeutics, the latter category is of course of immediate
interest.
The UPS may be particularly important for the interferon response.
The ubiquitin-like (Ubl) protein ISG15 (interferon-stimulated gene
product of 15 kDa) shows signiﬁcant homology to ubiquitin and is cova-
lently attached to target proteins in a similar manner (Haas et al., 1987;
Loeb &Haas, 1992). A number of DUBs have been shown to have impor-
tant roles in interferon signaling, including OTUD5 (DUBA) (Kayagaki
et al., 2007), OTUB1/OTUB2 (Li et al., 2010), USP3 (Cui et al., 2014),
USP17 (Chen et al., 2010) and USP25 (Zhong et al., 2013). Conversely,
viruses have been shown to encodeDUB enzyme activities that counter-
act interferon induction as a means of escaping innate immune re-
sponses (Wang et al., 2011; van Kasteren et al., 2012).
TheUPS is involved atmultiple levels of theMet receptor tyrosine ki-
nase pathway (Buus et al., 2009). The scattering response of epithelial
cells is quite complex and includes loss of cell–cell adhesion and induc-
tion of cellular motility. Using siRNA library screening, 12 DUBs were
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scattering response of A549 cells, including USP3, USP30, USP33, USP47
and ATXN3L (Buus et al., 2009).
A number of DUBs are involved in direct or indirect regulation of the
stability of the p53 tumor suppressor protein: USP2, USP7, USP10,
USP22, USP42 and OTUD5. A large body of evidence points to mutant
p53 in tumors having gain-of-function and decreasing the stability of
mutant p53 may be a viable therapeutic strategy. Similar to wild-type
p53, mutant p53 is regulated by Mdm2 (Terzian et al., 2008).
3.2. Genetic alterations affecting DUB genes are found in human tumors
Mutations in genes encoding DUBs have been detected in human
cancers, illuminating the importance of DUBs in processes of direct im-
portance for cancer cell biology. Germline mutations in the CYLD gene
were identiﬁed in kindreds with familial cylindromatosis and sporadic
cylindromas (Bignell et al., 2000) and also in patients with Brooke–
Spiegler syndrome and familial trichoepithelioma (Poblete Gutierrez
et al., 2002). These are autosomal dominant inherited diseases associat-
ed with the development of multiple skin tumors of the head and neck.
Mutations are thought to affect the catalytic activity of CYLD enzyme.
Aberrant USP6 expression, resulting from gene translocation, has been
found to be causative in most instances of aneurysmal bone cysts
(Oliveira et al., 2004), locally aggressive bone lesions that occur during
the ﬁrst two decades of life (Rapp et al., 2012). The translocation,
t(16;17)(q22;p13), fuses the promoter for the osteoblast cadherin 11
gene to the full-length USP6 gene resulting in upregulated USP6 tran-
scription. A20 (TNFAIP3/tumor necrosis factor alpha-induced protein
3) is required to terminate NFκB signaling in response to tumor necrosis
factor. InactivatingA20mutationswere reported to be frequently occur-
ring in cases of marginal zone lymphoma (Novak et al., 2009). Further-
more, an almost complete loss of A20 mRNA expression has been
observed in cases of Non-Hodgkin's Lymphoma (Durkop et al., 2003).
Various types of genetic alterations have been found in the gene
encoding the BAP1 deubiquitinase in various diseases, including lung
and breast tumors, clear cell renal cell carcinomas andmalignant pleural
mesotheliomas (Buchhagen et al., 1994; Jensen et al., 1998; Jensen &
Rauscher, 1999; Bott et al., 2011; Pena-Llopis et al., 2012).Mutations oc-
curring in BAP1were reported to lead to loss of deubiquitinating activity
(Ventii et al., 2008). Finally, the USP42 gene is a fusion partner in the
(7;21)(p22;q22) translocation in acute myeloid leukemia (AML)
(Paulsson et al., 2006).
3.3. Association of DUBs with processes relevant to cancer
A short overview of DUB activities relevant to cancer is presented
below. We have focussed on mechanisms with potential translational
potential in cancer. Theﬁeld is growing rapidly, and due to space restric-
tions the overview is not complete.
USP1 is involved in theDNAdamage response (Nijman et al., 2005a).
USP1 regulates DNA repair and the Fanconi anemia pathway through its
association with UAF (USP1 associated factor 1; WDR48) and through
its deubiquitination of two critical DNA repair proteins, FANCD2-Ub
and PCNA-Ub. USP1 is activated by complex formation with UAF1
(USP1 associated factor 1;WDR48). USP1 deubiquitinates the DNA rep-
lication processivity factor, PCNA, as a safeguard against error-prone
translesion synthesis of DNA (replication at sites of DNAdamage). Ultra-
violet (UV) irradiation inactivates USP1 through an autocleavage event,
thus enabling monoubiquitinated PCNA to accumulate and to activate
translesion DNA synthesis (Huang et al., 2006). UAF1-deﬁcient cells
have severe defects in homologous recombination (HR)-mediated
double-strand break (DSB) repair and are hypersensitive to DNA dam-
aging agents such as camptothecin (Murai et al., 2011).
USP2 and its different isoforms have been extensively studied by
cancer biologists. USP2a is known to associate with Mdm2 and MdmX
and has the capacity to deubiquitinate these proteins (Stevenson et al.,2007; Allende-Vega et al., 2010). In distinction to USP7/HAUSP, Usp2a
does not appear to bind to p53. Overexpression of USP2a leads to in-
creased cellular levels of Mdm2/MdmX and degradation of p53
(Fig. 4). As expected, suppression of endogenous USP2a leads to desta-
bilization of Mdm2 and accumulation of p53 protein. Usp2a has also
been shown to interact with and deubiquitinate Aurora-A (Shi et al.,
2011). The Aurora-A protein is localized to centrosomes and is essential
for centrosome duplication (Meraldi et al., 2004). Knockdown of USP2a
leads to reduced protein levels of Aurora-A and abnormal mitosis. Fur-
ther studies have shown that Usp2a targets cyclin A1 (Kim et al.,
2012) and cyclin D (Shan et al., 2009), leading to increases in the ex-
pression of this protein and enhancement of cell proliferation. Fatty
acid synthase is known to be overexpressed in many epithelial tumors
and important for cell survival (Dhanasekaran et al., 2001) and USP2a
has been demonstrated to interact with this enzyme (Graner et al.,
2004). USP2a is androgen-regulated and overexpressed in prostate can-
cer, and functional inactivation of the DUB has been shown to enhance
apoptosis of prostate cancer cells (Graner et al., 2004). Inhibition of
Usp2a may be a general strategy to activate p53 in tumor cells
(Allende-Vega & Saville, 2010), resulting in the induction of tumor apo-
ptosis, at least under some conditions. For example, siRNA depletion of
USP2a inducedmoderate levels of apoptosis in prostate cancer cell lines
after 48 h (Graner et al., 2004). In contrast to these reports, it has been
reported that knock-down of USP2c results in apoptosis, while targeting
USP2a does not affect cell survival (Mahul-Mellier et al., 2012). USP2a is
a candidate therapeutic target in oncology, the inhibition of which is ex-
pected to lead to decreased cell proliferation (Fig. 4).
USP5 is commonly referred to as isopeptidase T and is known to
show speciﬁcity for unanchored polyubiquitin chains (Hadari et al.,
1992). Deletion of the yeast homolog of the USP5 gene (Ubp14) results
in accumulation of free ubiquitin chains. It was proposed that
isopeptidase T facilitates proper proteasome function by preventing un-
anchored ubiquitin chains competing for ubiquitin receptors on the 19S
proteasome (Amerik et al., 1997). Suppression of USP5/isopeptidase T
has been shown to increase both the levels and transcriptional activity
of p53 without alteringMdm2 stability (Dayal et al., 2009). The mecha-
nism whereby USP5 knockdown stabilizes p53 is by decreasing its
proteasome-mediated degradation. It was proposed that p53 is stabi-
lized due to competition between unanchored polyubiquitin chains
and ubiquitinated p53 in cells (Dayal et al., 2009).
USP7, also referred to asHAUSP, has also been identiﬁed as a key reg-
ulator of p53 activity (Fig. 4). p53 levels are predominantly regulated by
the E3 ubiquitin ligase Mdm2, leading to low intracellular concentra-
tions during normal homeostasis. USP7 was ﬁrst identiﬁed as Herpes
virus-associated cellular factor (HAUSP) (Everett et al., 1997) and later
shown to deubiquitinate and stabilize p53 (Li et al., 2002). USP7 can
also deubiquitinate and stabilize Mdm2 providing an alternative level
of p53 regulation (Cummins et al., 2004; Li et al., 2004). Polycomb re-
pressive complex 1 (PRC1) is known to monoubiquitinate histone
H2A. BothUSP7 andUSP11 co-purifywith human PRC1-type complexes
and regulate the ubiquitination of some components of these com-
plexes (Maertens et al., 2010). Removal of USP7 or USP11 in primary
human ﬁbroblasts results in increased expression of the INK4a tumor
suppressor and proliferative arrest (“senescence”).
USP8/UBPY (themammalian ortholog of budding yeast Ubp4/Doa4)
was described as a DUB that accumulates upon growth stimulation of
human ﬁbroblasts (Naviglio et al., 1998). Down-regulation of USP8/
UBPY prevents ﬁbroblasts from entering S-phase in response to serum
stimulation (Naviglio et al., 1998). USP8 has subsequently been found
to be involved in EGFR receptor turnover. Following ligand stimulation,
the EGFR is ubiquitinated by the E3 ligase Cbl, resulting in receptor in-
ternalization. The internalized receptor is subsequently deubiquitinated
by USP8 prior to lysosomal degradation (Alwan et al., 2003; Row et al.,
2006; Alwan & van Leeuwen, 2007).
FLIPS is a suppressor of TRAIL-induced apoptosis. FLIPS stability is
controlled by the E3 ubiquitin ligase AIP4 (atrophin-interacting protein
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Fig. 4. USP2a and USP7 control the stability of p53 and other important cellular regulators. (A) USP2a deubiquitinates and stabilizes Mdm2/MdmX. Suppression of USP2a leads to desta-
bilization of Mdm2 and accumulation of p53 protein (right). Usp2a has also been shown to deubiquitinate Aurora-A (a protein essential for centrosome duplication). Downregulation of
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levels of these proteins (right). (B) USP7 deubiquitinates both p53 and HDM2. Inhibition of USP7 enzyme activity leads to stabilization of p53 protein.
38 P. D'Arcy et al. / Pharmacology & Therapeutics 147 (2015) 32–544) (Panner et al., 2010). The stability of the AIP4 ligase is in its turn reg-
ulated by USP8. Interestingly, USP8 levels are regulated by the PTEN–
Akt signaling pathway (Panner et al., 2010). Increased AKT phosphory-
lation therefore leads to decreased levels of FLIPS and resistance to TRAIL
(Fig. 5). USP8 is required for stabilization of another E3 ubiquitin ligase,
Nrdp1 (Wu et al., 2004a) (Fig. 5). Nrdp1 is involved in the regulation of
steady-state ErbB3 levels by mediating growth factor-independentdegradation of this receptor (Diamonti et al., 2002; Qiu & Goldberg,
2002). Akt-mediated phosphorylation of the USP8 threonine residue
T907 has been found to regulate USP8 stability (Cao et al., 2007). Expo-
sure to ErbB3 ligand (neuregulin-1; NRG1) stabilizes USP8, leading to
stabilization of Nrdp1.
USP9x is an X-linked ubiquitin speciﬁc protease (also known as
FAM; fat facet in mouse). The corresponding Drosophila protein faf (fat
PTEN wt
pAkt
FLIPs
U
U
U
U
U
U
U
U
U
U
USP8
AIP4 AIP4
U
U
U
U
U
+
+
FLIPs
FLIPs
PS
Trail sensitive
PTEN loss
pAkt
FLIPs
USP8
AIP4 AIP4
U
U
U
U
U
Trail resistant
USP8
USP8
Fig. 5.USP8 regulates sensitivity to TRAIL. The stability of theAIP4 E3 ubiquitin ligase (atrophin-interacting protein 4) is regulated byUSP8. AIP4 regulates the stability of FLIPS. The protein
levels ofUSP8 levels are under control of the PTEN–Akt signalingpathway (USP8 T907 is phosphorylated byAkt). Since FLIPS is a suppressor of TRAIL-induced apoptosis, the activity level of
the PTEN–AKT pathway is a determinant of the degree of TRAIL sensitivity (increased AKT activity leads to increased levels of FLIPS).
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determination in the Drosophila eye (Fischer-Vize et al., 1992). USP9x
is an essential component of the TGF-β signaling pathway. The activity
of the Smad4 transcription factor is impeded by monoubiquitination
of lysine 519, a process which is counteracted by USP9x (Dupont et al.,
2009). USP9x has also been implicated in the regulation of MAPK path-
ways. USP9X supports ASK1-mediated signaling by preventing
proteasomal degradation of activated ASK1 (Nagai et al., 2009). USP9x
was recently identiﬁed as a tumor suppressor gene for pancreatic ductalp53
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Adapted from Yuan et al. (2010).preneoplasia using an approach of transposon-mediated insertional
mutagenesis (Perez-Mancera et al., 2012). Low USP9X protein and
mRNA expression in human pancreatic ductal tumor was found to cor-
relate with poor patient survival. Finally, USP9x has been shown to sta-
bilize the pro-survival protein MCL1 (Schwickart et al., 2010). MCL1 is
expressed at low levels in most cell types due to rapid turn-over due
to the action of ubiquitin ligases, but is expressed at high levels in hema-
tologicalmalignances such as B-cell lymphomas, chronicmyeloid leuke-
mia and multiple myeloma. A correlation between USP9x expressionNucleus Cytoplasm
p53 Targets
Genotoxic stress
Usp10
U
Usp10
P
U
U
U
p53p53
p53
Mdm2p53
ATM
is phosphorylated by ATM (Ataxia telangiectasia mutated) after DNA damage. Phosphor-
ced p53 nuclear export and degradation. IncreasedUSP10 expression in p53mutant cancer
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fuse large B-cell lymphomas (Schwickart et al., 2010).
USP10 is amainly cytoplasmicDUBwhichdeubiquitinates p53 and re-
versesMdm2-induced p53 nuclear export and degradation (Fig. 6) (Yuan
et al., 2010). USP10 is stabilized after DNA damage and translocates to the
nucleus to activate p53. USP10 is phosphorylated by ATM (Ataxia telangi-
ectasia mutated) at Thr42 and Ser337. USP10 suppresses tumor cell
growth in cells with wild-type p53. Increased USP10 expression in mu-
tant p53 background increases p53 levels and promotes cancer cell prolif-
eration, while downregulation of USP10 inhibits cancer cell growth.
USP10 also suppresses ubiquitination of the sirtuin family histone
deacetylase SIRT6, leading to protection of SIRT6 from degradation by
the proteasome (Lin et al., 2013). This indirectly leads to decreased tran-
scriptional activity of c-Myc, and inhibition of cancer cell proliferation and
tumor formation. USP10 is not exclusively found in the cytoplasmandhas
indeed been reported to deubiquitinate the histone variantH2A.Z (Draker
et al., 2011). Interestingly, other histone-modifying enzymes, including
histone acetyltransferases, the deacetylase SirT1 (Vaziri et al., 2001) and
the demethylase LSD1 (Huang et al., 2007), have all been shown to target
andmodify p53 aswell. The autophagy regulator Beclin1 has been report-
ed to control the stability of USP10, and also of USP13 (Liu et al., 2011a).
USP11 has been identiﬁed as an IκBα-associated deubiquitinase ca-
pable of deubiquitinating IκBα in vitro (Sun et al., 2010). IκBα
ubiquitination is required for IκBα degradation and NFκB activation.
Knock-down of USP11 expression enhances TNFα-induced IκBα
ubiquitination and NF-κB activation. USP11 is therefore important for
downregulation of TNFα-mediated NFκB activation by modulating
IκBα stability. USP11 is also involved in the regulation of TGFβ signaling
by deubiquitinating the type I TGFβ receptor (Al-Salihi et al., 2012).
USP11 interacts with SMAD7 and enhances TGFβ signaling. Finally, the
USP11 protein has been found in complexes with the DNA damage
repair-associated protein BRCA2 (Schoenfeld et al., 2004). BRCA2 does
not, however, appear to be a physiologic substrate of USP11 andmay in-
stead function as a molecular bridge between USP11 and its substrates.
USP12 deubiquitinates non-activated Notch and is required for the
lysosomal degradation of this protein (Moretti et al., 2012). USP12
down-regulation leads to an increased level of Notch molecules at the
cell surface. USP12 (and USP46) also acts as a histone H2A and H2B
deubiquitinase that regulates Xenopus development (Joo et al., 2011).
USP13 is a deubiquitinating enzyme for MITF (microphthalmia-as-
sociated transcription factor), the activity of which leads to stabilization
and upregulation of MITF protein levels. MITF is a basic helix–loop–
helix-leucine zipper transcription factor and an important regulator in
the development and survival of melanocytes. Ampliﬁcation of MITF is
oncogenic in 10–20% of melanomas (Garraway et al., 2005) and inhibi-
tion of MITF induces melanoma cell death regardless of whether the
gene is ampliﬁed or not (McGill et al., 2002). Conversely, suppression
of USP13 (by siRNA knock-down) leads to a dramatic loss of MITF pro-
tein. USP13 has been found to be essential for melanoma growth in
animal tumor models and targeting this enzyme may provide a thera-
peutic opportunity.
USP15 regulates the TGF-β pathway and is believed to be important
for the proliferation of glioblastoma cells (Eichhorn et al., 2012). USP15
binds to the SMAD7–SMAD E3 ligase complex and deubiquitinates and
stabilizes the type I TGF-β receptor (TGFβR-I), leading to an enhanced
TGF-β signal. High expression of USP15 correlates with high TGF-β ac-
tivity, and the USP15 gene is found ampliﬁed in glioblastoma, breast
and ovarian cancer. Glioblastoma patients with increased (N2.5) USP15
copy numbers in their tumors have a shorter overall survival time
(Eichhorn et al., 2012). Depletion of USP15 decreases the oncogenic ca-
pacity of patient-derived glioma-initiating cells due to the repression of
TGF-β signaling, offering a therapeutic opportunity. USP15 is also a DUB
for another set of components of the TGF-β signaling pathway, the
receptor-activated SMADs (R-SMADs) (Inui et al., 2011). USP15opposes
R-SMAD monoubiquitination, preventing promoter recognition. USP15
has been found to be associated with the COP9 signalosome where ithas been suggested to show a quality control-type function, prevent im-
proper autoubiquitination of labile ligases (Hetfeld et al., 2005; Wee
et al., 2005).
USP16 (also known as Ubp-M) is phosphorylated at the onset of mi-
tosis by cdc-2/cyclin B complexes (Cai et al., 1999). USP16 is responsible
for deubiquitinatingH2Aduringmitosis. H2Adeubiquitination byUSP16
is a prerequisite for subsequent phosphorylation of histone H3 on Ser10
and for chromosome segregation during mitosis (Joo et al., 2007).
USP17 has been shown to have a critical role in cell migration and to
be a potential target for anti-metastatic therapy (de la Vega et al., 2011).
Depletion of USP17 blocks chemokine-induced subcellular relocalization
of GTPases essential for cell motility (Cdc42, Rac and RhoA). USP17 also
negatively regulates the activity of Ras-converting enzyme 1 (RCE1)
(Burrows et al., 2009). RCE1 cleaves RAS at its C-terminal CAAX motif
and expression of USP17 leads to impaired Ras membrane localization
and activation.
USP18 is a deubiquitinase of the ISG15 protein (ISG15: interferon-
stimulated gene 15) (Malakhov et al., 2002). Mice that are genetically
defective in USP18 are hypersensitive to interferon. USP18 was subse-
quently shown to block the interaction between JAK kinase and the
IFN receptor (Malakhova et al., 2006). All-trans-retinoic acid treatment
increases USP18 expression in acute promyelocytic leukemia (APL)
cells, leading to stabilization of the PML/RARα protein. USP18 knock-
down decreases PML/RARα protein levels and inhibits APL cell prolifer-
ation (Guo et al., 2010).
USP19 has been described to be involved in a number of cellular pro-
cesses. USP19 is a membrane-anchored DUB localized to the endoplas-
mic reticulum and a key component of ERAD (endoplasmic-reticulum
associated degradation) (Hassink et al., 2009). USP19 has been sug-
gested to participate in a late step of the protein quality-controlmachin-
ery by rescuing ERAD substrates that have been retro-translocated to
the cytosol. Interestingly, USP19 contains a co-chaperone-like domain,
which may be involved in the proposed rescue process. USP19 also in-
teracts with HIF-1α, promoting its stability and an appropriate hypoxia
response (Altun et al., 2012). USP19 stabilizes the KPC1 ubiquitin ligase,
involved in regulation of the p27Kip1 cyclin-dependent kinase inhibitor
(Lu et al., 2009). Depletion of USP19 by RNA interference leads to
p27Kip1 accumulation and inhibition of the proliferation of ﬁbroblasts
(Lu et al., 2009). The ability of USP19 to regulate cell proliferation and
p27Kip1 levels appears to be cell context-dependent, and is lost when ﬁ-
broblasts are transformed by an oncogenic form of Ras (Lu et al., 2011).
USP19 also interacts with the inhibitors of apoptosis (IAPs) c-IAP1 and
c-IAP2 (Mei et al., 2011). Knockdown of USP19 decreases levels of
these c-IAPs, whereas overexpression results in increases in the levels
of these apoptosis inhibitors. Knock-down of USP19 enhances TNFα-in-
duced caspase activation and apoptosis in a c-IAP1- and c-IAP2-
dependent manner.
USP21 was found to be unique among cellular DUBs by showing
clear association with centrosomes and microtubules in a GFP-based
screen (Urbe et al., 2012). Binding to microtubules occurs via a novel
microtubule-binding motif at the N-terminus of USP21. Depletion of
USP21 is required for recovery from microtubule depolymerization
and is required for nerve growth factor-induced neurite outgrowth in
PC12 cells (Urbe et al., 2012). USP21 catalyzes the hydrolysis of
ubiquitinated H2A (Nakagawa et al., 2008; Okuda et al., 2013). During
chromatin assembly in vitro, ubiquitinated H2A represses di- and
trimethylation of H3K4. USP21 relieves this repression and is believed
to be associated with de-repression of transcriptional initiation by
inhibiting H3K4 methylation.
USP22 was described as one of 11 death-from-cancer signature
genes that are critical in controlling cell growth and death (Glinsky,
2006). USP22 is a positive regulator of the histone deacetylase Sirt1
(Lin et al., 2012). USP22-mediated stabilization of Sirt1 leads to de-
creases in p53 acetylation and suppression of p53 function. In contrast,
knock-down of USP22 leads to destabilization of Sirt1, increases in p53
acetylation and induction of p53-dependent apoptosis. USP22 has,
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H2B (Zhao et al., 2008; Joo et al., 2011).
USP25 is suppressed bymiR-200c, leading to inhibition of tumor cell
migration and invasion in vitro and inhibition of lungmetastasis forma-
tion in vivo (Li et al., 2014a). USP25 protein andmRNA level expression
were elevated in non-small cell lung cancer tumors and correlated with
clinical stage and lymphatic node metastasis of patients (Li et al.,
2014a). USP25 has been shown to interact with the SYK non-receptor
tyrosine kinase (Cholay et al., 2010) and has been implicated in ERAD
(Blount et al., 2012)
USP28 plays a critical role in regulation of the Chk2–p53–PUMA-sig-
naling pathway, important for DNA-damage-induced apoptosis in re-
sponse to double-strand breaks (Zhang et al., 2006; Bohgaki et al.,
2013). USP28 is required for stabilization of Chk2 and 53BP1 in response
to DNA damage. Upon DNA damage in the G2 phase of the cell cycle,
Usp28 protects claspin from APC/CCdh1-mediated degradation. Usp28
permits claspin-mediated activation of Chk1 in response to DNA
damage.
The transcription factor MYC is dysregulated in a number of neo-
plasms, including colorectal tumors (Diefenbacher et al., 2014) and
bladder cancers (Guo et al., 2014a). Similar to other transcription factors
such as p53, c-MYC is difﬁcult to target directly using small molecules.
Interestingly, USP28 is required for the stability of theMYC oncoprotein
in human tumor cells (Fig. 7) (Popov et al., 2007). USP28 controls MYC
stability by counteracting the activity of the SCFFBW7 ubiquitin ligase
complex (Popov et al., 2007). It was recently demonstrated that USP28
antagonizes the ubiquitin-dependent degradation of not only MYC, but
also of c-JUN and NOTCH (Diefenbacher et al., 2014). Mice lacking
USP28 showed reduced intestinal cell proliferation and fewer intestinal
tumors. Depletion of USP28 reduced tumor size and increased the
lifespan of tumor-bearing mice.
The chromatin modulator LSD1 controls cellular pluripotency
through histone demethylation and is overexpressed in many tumor
types. USP28 has been shown to stabilize LSD1 via deubiquitination
(Wu et al., 2013). Knock-down of USP28 using RNA interference results
in destabilization of LSD1 and leads to the suppression of cancer stem
cell-like characteristics and inhibition of tumorigenicity in vivo (Wu
et al., 2013). Another function of USP28 is its ability to antagonize the
ubiquitin ligase Fbw7, resulting in stabilization of the HIF-1αN-Myc Max
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Fig. 7. USP28 regulates c-Myc stability. USP28 binds to c-MYC and N-MYC through an in-
teraction with the F-box protein FBW7α. USP28 stabilizes MYC in the nucleus. Stabiliza-
tion of MYC by USP28 is essential for the proliferation of tumor cells.transcription factor (Flugel et al., 2012). The inhibition of the enzymatic
activity of USP28 may be a potential target for cancer therapy.
USP29 has attracted interest following the ﬁnding that the gene
encoding this DUB is imprinted and is transcribed mainly from the pa-
ternal allele (Kim et al., 2000). USP29 is involved in the control of the
stability of claspin, a protein that has a key role in the ATR-Chk1 branch
of the DNA damage checkpoint (Martin et al., 2014). USP29 knockdown
results in an impaired phosphorylation of Chk1 after DNA damage.
Claspin is also involved in the process of DNA replication and USP29-
depleted cells display defects in S-phase progression (Martin et al.,
2014). In addition, USP29 has been found to be transcriptionally in-
duced following oxidative stress, where it contributes to the full induc-
tion of a p53 response (Liu et al., 2011b).
USP33 (also called VDU1) was originally discovered as a DUB which
binds to the pVHL-containing E3 ligase complex targeted for ubiquitin
(Ub)-mediated degradation (Li et al., 2002). The USP33 homolog VDU2
is also referred to as USP20. USP33 has been found to be localized to
the secretory pathway, and one splice variant accumulates at the Golgi
apparatus (Thorne et al., 2011). Substrates identiﬁed so far for USP33
and/or its homolog USP20/VDU2 include the RAS-like GTPase RALB
(Simicek et al., 2013), type 2 iodothyronine deiodinase (D2) (Curcio-
Morelli et al., 2003) and HIF-1α (Li et al., 2005). Deubiquitylation of
RALB by USP33 promotes the assembly of complexes which contain
Beclin-1 and which stimulate autophagosome formation (Simicek
et al., 2013). USP33 also binds to the Robo1 receptor and is required
for the responsiveness of breast cancer cells to the migration factor Slit
(Yuasa-Kawada et al., 2009). USP33 deubiquitinates the CP110 protein,
an important regulator of centrosome duplication (Li et al., 2013). Over-
expression of CP110 leads to centrosome over-duplication and genomic
instability (Chen et al., 2002a). CP110 levels are controlled through
ubiquitination by the SCF ligase complex and through deubiquitination
by USP33. During duplication and elongation of centrioles in S and G2/
M phases, USP33 localizes to centrioles. Down-regulation of USP33 de-
stabilizes CP110 and thereby inhibits centrosome ampliﬁcation and mi-
totic defects (Li et al., 2013).
USP34 is encoded by a gene region on 2p15-16.1 which is ampliﬁed
during progression of follicular lymphoma (FL) to diffuse large B-cell lym-
phoma (DLBCL) (Kwiecinska et al., 2014). Haploinsufﬁciency for USP34
appears to affect the regulation of developmental processes (Fannemel
et al., 2014). USP34 has been reported to act downstream of the β-
catenin destruction complex in the Wnt pathway (Lui et al., 2011).
Knock-down of USP34 by RNA interference leads to degradation of axin,
a scaffolding protein, and to inhibition of β-catenin-mediated transcrip-
tion. Finally, USP34 has a role in proper maintenance of genome stability
due to its role in stabilizing the E3 ligase RNF168, important for assembly
of K63-linked chains at DNA double strand breaks (Sy et al., 2013).
USP42 is a fusion partner in the (7;21)(p22;q22) translocation in
acute myeloid leukemia (AML) (Paulsson et al., 2006). The genomic
breakpoint is in intron 7 of RUNX1 and intron 1 of USP42. The RUNX1
transcription factor is a key regulator of hematopoiesis and is involved
in numerous translocations in AML (Osato, 2004). USP42 was subse-
quently described as an additional deubiquitinating enzyme for p53,
similarly to USP2a, USP7 and USP10. USP42 was reported not to affect
the basal levels of p53, but to be important during the early phase of a
stress response, helping to rapidly induce p53 levels (Hock et al., 2011).
USP44 is an important regulator of the mitotic spindle checkpoint.
USP44 prevents the premature activation of the anaphase-promoting
complex (APC), an ubiquitin ligase that promotes sister chromatid sep-
aration. This is achieved by stabilizing the APC-inhibitory Mad2–Cdc20
complex (Stegmeier et al., 2007a). Cells that overexpress Usp44 have
been found to be prone to chromosome segregation errors and
aneuploidization (Zhang et al., 2011; Zhang et al., 2012). USP44 has
also been shown to be a H2B deubiquitinase (Fuchs et al., 2012).
USP47 is responsible for deubiquitination the key base excision re-
pair (BER) DNA polymerase (Pol β) (Parsons et al., 2011). Knockdown
of USP47 results in decreased levels of Pol β and a deﬁciency in BER.
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sine kinase-activated scattering response of epithelial cells (Buus et al.,
2009). USP47 also interacts with the E3 ubiquitin ligase SCF(beta-
Trcp) (Skp1/Cul1/F-box protein beta-transducin repeat-containing pro-
tein). Depletion of USP47 increases Cdc25A levels in cells and decreases
cell survival, suggesting possibilities of therapeutic intervention
(Peschiaroli et al., 2010).
USP50 is believed to be involved in repressing entry into mitosis fol-
lowing activation of the DNA damage checkpoint (Aressy et al., 2010).
USP50 accumulates in the nucleus in response to treatment with DNA
damaging agents. HSP90 is a major interacting partner for USP50 and
depletion of USP50 results a loss in accumulation of the HSP90 client
Wee1.
CYLD germline mutations occur in familial cylindromatosis and
some other rare autosomal dominant inherited disorders associated
with the development of multiple skin tumors of the head and neck
(Bignell et al., 2000; Poblete Gutierrez et al., 2002). Hyperactive Wnt
signaling has been demonstrated in CYLD mutant human cylindroma
tumors (Tauriello et al., 2010). The underlyingmechanism of activation
has been shown to be via enhanced K63-linked ubiquitination of Dvl
(Dishevelled), the cytoplasmic effector of Frizzled, in the absence of
functional CYLD (Tauriello et al., 2010). An important function of CYLD
is regulation of NFκB activation (Trompouki et al., 2003). CYLD inhibits
NFκB-mediated activation by different TNF receptor family members
due to deubiquitination and inactivation of TNFR-associated factor 2
(TRAF2) and TRAF6. It was later shown that CYLD removes K63-linked
polyubiquitin chains from the Bcl-3 protein, resulting in retention of
Bcl-3 in the cytoplasm (Massoumi et al., 2006). Bcl-3 associates with
the NFκB p50 or p52 subunits and enhances cell proliferation through
activation of the cyclin D1 promoter. In CYLD-deﬁcient keratinocytes,
Bcl-3 accumulates in the nucleus, leading to activation of NFkB target
genes. CYLD also has another cell-cycle regulatory function, being im-
portant for proper regulation of mitotic entry (Stegmeier et al., 2007b).
UCHL1 was identiﬁed as being overexpressed in lung adenocarci-
nomas using a proteomics approach (Chen et al., 2002b). UCHL1 over-
expression in tumors was associated with patients having a smoking
history. Interestingly, UCHL1 was reported to be consistently up-
regulated in airway epithelial samples obtained from smokers, com-
pared with nonsmokers (Carolan et al., 2006). Overexpression of
UCHL1was speculated to represent an early event in the transformation
process of normal lung epithelium (Carolan et al., 2006). In contrast to
these ﬁndings, the UCHL1 genewas found to be silenced in giant cell tu-
mors of bone (Fellenberg et al., 2010). Silencing was associated with
methylation of the CpG island covering the UCHL1 promoter. The
UCHL1 gene has also been found to be silenced by methylation in
colon cancer cell lines (Fukutomi et al., 2007).
BAP1 (BRCA1 associated protein-1) is a nuclear-localized DUB of the
UCH family originally identiﬁed as an interacting partner of the BRCA1
tumor suppressor protein (Jensen et al., 1998). BAP1 has not been dem-
onstrated to deubiquitinate BRCA1, but fulﬁlls various criteria of having
a tumor suppressor function. Deletions and missense mutations in the
BAP1 gene are found in lung and breast tumors and lung cancer cell
lines (Buchhagen et al., 1994; Jensen et al., 1998; Jensen & Rauscher,
1999). The BAP1 protein is also inactivated in a fraction of clear cell
renal cell carcinomas (RCC) (Pena-Llopis et al., 2012) and BAP1
inactivating mutations have been demonstrated in ~25% of malignant
pleural mesotheliomas (Bott et al., 2011). Cancer-associated BAP1 mu-
tants are deﬁcient in deubiquitinating activity (Ventii et al., 2008).
BAP1 can suppress tumorigenicity of lung cancer cells in athymic nude
mice (Ventii et al., 2008). BAP1 loss sensitizes RCC cells in vitro to
genotoxic stress (Pena-Llopis et al., 2012). BAP1 interacts with the tran-
scriptional cofactor HCF-1 (host cell factor 1). By regulating HCF-1 pro-
tein levels, BAP1 may be involved in cell cycle control by associating
with genes involved in G1–S transition (Misaghi et al., 2009).
OTUB enzymes (OTU domain-containing ubiquitin aldehyde-
binding proteins) constitute a subfamily of 14 DUBs characterized byan ovarian tumor (OTU) domain (Borodovsky et al., 2002; Balakirev
et al., 2003). Ovarian tumor domain DUBs show speciﬁcity for different
Ub chain linkages. OTUB1 and A20 are speciﬁc to K48-linked chains,
Cezanne shows speciﬁcity to K11-linked chains and TRABID cleaves
K29- and K33-linked chains (Eletr & Wilkinson, 2014).
OTUB1 inhibits UBC13 (also known as UBE2N) and other E2 en-
zymes. UBC13 heterodimerizes with UEV1A to synthesize K63-linked
polyubiquitin chains at double strand breaks in a process also requiring
the ubiquitin ligase (E3) RNF168 (Stewart et al., 2009). OTUB1 directly
suppresses MDM2-mediated p53 ubiquitination, and overexpression
of OTUB1 leads to stabilization and activation of p53 (Sun et al., 2012).
Monoubiquitination of OTUB1 increases the interaction with UbcH5,
resulting in a suppression of UbcH5 activity (Li et al., 2014b). OTUB1
deubiquitinates estrogen receptor α (ERα) and negatively regulates
ERα mediated transcription (Stanisic et al., 2009). OTUB1, as well as
OTUB2, negatively regulates virus-induced type I IFN induction and an-
tiviral responses by deubiquitinating TRAF3 and TRAF6 (Li et al., 2010).
OTUD1 was reported to be highly expressed in thyroid carcinomas
and anOTUD1 antibodywas able to distinguish carcinomas frombenign
lesions (Carneiro et al., 2014).
OTUD4 is a deubiquitinase which appears to be involved in XPC
recycling. OTUD4 has been demonstrated to interact with the
xeroderma pigmentosum complementation group C (XPC) protein
(Lubin et al., 2014).
OTUD5 (DUBA) is activated by phosphorylation (Huang et al., 2012)
and suppresses the type I interferon response by cleaving the
polyubiquitin chain from tumor necrosis factor receptor-associated fac-
tor 3 (TRAF3) (Kayagaki et al., 2007). In addition, OTUD5 is also a
deubiquitinating enzyme for p53 which is required for the stabilization
and the activation of a p53 response (Luo et al., 2013)
A20 (TNFα-induced protein 3 (TNFAIP3)) is an important negative
regulator of the transcription factor NFκB. A20 inhibits the NFκB path-
wayby removing the K63-linked polyubiquitin chains onRIP1 (receptor
interacting protein 1) (Wertz et al., 2004) and TRAF6 (TNF receptor-
associated factor 6) (Ma & Malynn, 2012) (Fig. 8). The N-terminus of
A20 contains an OTU domain whereas the C-terminal portion contains
seven zinc ﬁnger structures. A20 is considered as an ubiquitin-editing
enzyme with both DUB and E3 ligase activity (Ma & Malynn, 2012;
Shembade & Harhaj, 2012). During TNF-mediated stimulation, A20 ex-
pression levels increase, leading to deubiquitination of K63-linked
chains on the RIP1 protein, but after some hours A20 conjugates K48-
linked polyubiquitin chains on the same RIP1 substrate, triggering its
degradation by the proteasome. A20 acts as a tumor suppressor in lym-
phoid malignancies due to its NFκB inhibiting role (reviewed in Harhaj
and Dixit (2012)). As discussed in a previous section, the A20 gene is
mutated/deleted in various types of lymphoma (Honma et al., 2009;
Novak et al., 2009; Schmitz et al., 2009; Dong et al., 2011; Zhang et al.,
2012). In contrast, forced overexpression of A20 in breast cancer cells
leads to tamoxifen resistance (Vendrell et al., 2007).
Cezanne is an OTU deubiquitinase with sequence homology to A20
(Evans et al., 2003). Cezanne is induced by TNF-α in cultured cells and
silencing of Cezanne leads to elevated NFκB activity in response to this
cytokine (Enesa et al., 2008). It was suggested that miR-218 regulates
the ability of TGF-β to induce myoﬁbroblast differentiation via a path-
way involving Cezanne (Guo et al., 2014b).
Ataxin-3 was identiﬁed as the protein product of the Machado–
Joseph disease gene locus (Kawaguchi et al., 1994). Machado–Joseph
disease is a dominantly inherited form of spinocerebellar ataxia.
Ataxin-3 contains a poly-glutamine stretch, the expansion of which
is associated with the disease. Additional proteins (ataxin 3-like
and Josephin domain containing 1) showing pronounced homology
to ataxin-3 were later identiﬁed and named Josephins (Albrecht et al.,
2003). Ataxin-3 is a DUB which has been implicated in ERAD and the
regulation of autophagy. Ataxin-3 is a poly-glutamine containing
deubiquitinating enzyme (DUB) that interacts with the p97 ATPase
and with various shuttling factors such as HHR23A and -B (Boeddrich
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Adapted from Sun et al. (2010).
43P. D'Arcy et al. / Pharmacology & Therapeutics 147 (2015) 32–54et al., 2006). Ataxin-3 associates with parkin, HDAC6 (histone
deacetylase 6) and other aggresome components (Wang et al., 2012).
Ataxin-3 trims K63-linked chains from misfolded ubiquitinated pro-
teins and enhances the rate of aggresome formation (Burnett &
Pittman, 2005). Josephin DUBs have roles in cell signaling: all three
members are implicated in regulation of PTEN (phosphatase and tensin
homolog) expression (Sacco et al., 2014). Interestingly, DUB-mediated
regulation occurs at the level of transcription by an unidentiﬁed mech-
anism. Importantly, knock-down of ataxin-3 using siRNA leads to PTEN
induction and downregulation of PI3K signaling.
BRCC36 is a member of the JAMM (JAB1/MPN/MOV34
metalloenzyme) class of DUBs. BBRC36 was isolated as a constituent
of an enzyme complex also containing BRCA1, BRCA2, and RAD51
(Dong et al., 2003). BRCA1 is recruited to DNA double-strand breaks
by the ubiquitin-binding protein RAP80 (Sobhian et al., 2007). The
role of BRCC36 in this complex may be to terminate signaling follow-
ing completion of DNA repair (Shao et al., 2009). Cancer-associated
BRCA1 mutations decrease the association between BRCC36 and
BRCA1 (Dong et al., 2003). Interestingly, aberrant expression ofBRCC36 was observed in breast cancer cell lines and tumors (Dong
et al., 2003). Knock-down of BRCC36 in breast cancer cells leads to
sensitization to ionizing radiation (Chen et al., 2006). This effect
was found to be associated with a loss of BRCA1 activation.4. Small molecule DUB inhibitors
Similar to protein kinase inhibitors, a span of small molecule DUB in-
hibitors has beendescribed ranging frombroad pan-enzyme inhibitors to
speciﬁc inhibitors of single DUB enzymes. Also in analogywith kinase in-
hibitors, unspeciﬁc inhibitors are likely to elicit more profound biological
effects but also to show stronger unspeciﬁc toxicity. Inhibition ofmultiple
DUBs is predicted to induce cellular changes such as (a) increased accu-
mulation of polyubiquitinated proteins/unanchored polyubiquitin chains
(if the proteasome/USP5 is inhibited); (b) declines in the pool of mono-
meric ubiquitin, (c) slower rates of polyubiquitin disassembly, (d) an
overall decrease in individual DUB activities, and (e) affect cellular
levels/activities of DUB-regulated oncoproteins (discussed by Kapuria
44 P. D'Arcy et al. / Pharmacology & Therapeutics 147 (2015) 32–54et al. (2010)). The subject has recently been reviewed elsewhere
(Edelmann et al., 2011; Buckley & Crews, 2014).
A number of individual DUBs have been reported to be involved in the
control of programmed cell death (apoptosis) (Ramakrishna et al., 2011).
An example is USP7 inhibition that results in decreased levels of Mdm2,
leading to stabilization of p53. Inhibition of multiple DUBs may be ex-
pected to amplify these affects (if they regulate essential substrates)
but may also be predicted to increase the quantity of polyubiquitinated
proteins/unanchored polyubiquitin chains. The inhibition of some
DUBs, particularly those associated with the proteasome, can lead to im-
paired proteasome function and accumulation of misfolded proteins in
cells. Such accumulation will lead to proteotoxicity and ultimately cell
death.4.1. Synthetic small molecule DUB inhibitors
USP7 (HAUSP) has attracted signiﬁcant interest from drug devel-
opers due to its role in controlling p53 stability. P022077was identiﬁed
as a speciﬁc USP7 inhibitor by Progenra (Tian et al., 2011). P5091 is an
inhibitor of USP7 and USP47 (Chauhan et al., 2012; Weinstock et al.,
2012) and was found to induce apoptosis of multiple myeloma cells re-
sistant to the 20S proteasome inhibitor bortezomib. Speciﬁcity was val-
idated using USP7 knockout cells. P5091 was reported to be well
tolerated by animals and to inhibit tumor growth (Chauhan et al.,
2012). Amore potent analog of P5091 has subsequently been described
(cpd 14) (Weinstock et al., 2012) (Table 1).
USP14 is one of the three distinct DUBs that are associated with
proteasomes (RPN11, UCHL5 and USP14). USP14 disassembles
proteasome-bound polyubiquitin chains from their distal tips. USP14
activity leads to suppression of substrate degradation by disengaging
the substrates from the proteasomes (Lee et al., 2011). A smallmolecule
inhibitor of USP14 (IU1; Fig. 9) has been described which indeed en-
hances proteasome function in cells (Lee et al., 2010). This compound
binds speciﬁcally to the activated, proteasome bound, form of USP14.
Increasing proteasomal-mediated degradation by IU1 or similar inhibi-
tors may be of therapeutic beneﬁt in diseases such as Alzheimer's dis-
ease (Lee et al., 2010). The situation appears to be quite complex,
however, since USP14 appears to be essential for the maintenance of
synaptic ubiquitin levels and the development of neuromuscular junc-
tions (Wilson et al., 2002; Chen et al., 2009). It is, however, quite possi-
ble that loss of USP14 protein does not elicit the same effect on cells as
inhibition of enzyme activity.Table 1
Synthetic small molecule DUB inhibitors.
Compound Reported activity/
target
Ref
P022077 USP7 (Tian et al., 2011)
P5091 USP7 (Chauhan et al., 2012)
Cpd 14 USP7 and USP47 (Weinstock et al., 2012)
P22077 USP7/USP47 (Altun et al., 2011)
HBX 41,108 USP7 (Colland et al., 2009)
HBX-19,818 USP7 (Reverdy et al., 2012)
HBX-28,258 USP7 (Reverdy et al., 2012)
HBX 90,397 USP8 (Edelmann et al., 2011)
Ethyloxyimino-9H-indeno
[1,2-b]pyrazine-2,3-
dicarbonitrile
USP8 (Colombo et al., 2010;
Byun et al., 2013)
IU1 USP14 (Lee et al., 2010)
Isatin O-acyl
oxime derivatives
UCHL1 (Liu et al., 2003)
LDN91946 UCHL1 (Mermerian et al., 2007)
LS1 UCHL3 (Ohayon et al., 2012)
NSC112200,
NSC267309
TRABID/ZRANB1 (Shi et al., 2012)
PR-619 Broad spectrum DUB
inhibition
(Edelmann et al., 2011)LDN-57444 is an isatin O-acyl oxime reported to selectively inhibit
UCHL1 (Liu et al., 2003). LDN-57444 is a reversible, competitive, and ac-
tive site-directed inhibitor. The inhibitor increased proliferation of the
H1299 lung tumor cell line but had no effect on a lung tumor line that
does not express UCHL1 (Liu et al., 2003). LDN-57444 was found to in-
crease the levels of polyubiquitinatedproteins and to induce apoptosis as-
sociatedwith ER stress in SK-N-SH neuroblastoma cells (Tan et al., 2008).
Pimozide (an anti-psychotic drug) and GW7647 (a PPAR-α agonist)
were identiﬁed as inhibitors of USP1/UAF1 in a high-throughput screen
(Chen et al., 2011). These drugs were found to act synergistically with
cisplatin in inhibiting proliferation of cisplatin-resistant non-small cell
lung cancer cells (Chen et al., 2011).
HBX 19,818 is a speciﬁc inhibitor of USP7 that covalently modiﬁes
the active Cys223 residue of this enzyme (Reverdy et al., 2012). LS1 is
an UCHL3 inhibitor which was identiﬁed in a FRET-based screen
where ﬂuorescently labeled ubiquitin was attached to substrates con-
taining quenchers (Ohayon et al., 2012). PR-619 is a general DUB en-
zyme inhibitor, but does not inhibit other classes of cysteine proteases
(Altun et al., 2011). LDN91946was identiﬁed in an in vitro screen for in-
hibitors of Ub-AMC activity (Mermerian et al., 2007). The compound
was reported to be a non-competitive inhibitor of UCHL1, but did not in-
hibit other cysteine proteases such as UCHL3, USP5 and caspase-3.4.2. DUB inhibition by cyclopentone prostaglandins
Fitzpatrick and coworkers (Mullally et al., 2001) originally reported
that cyclopentone prostaglandins of the PGJ2 class induce accumulation
of polyubiquitinated proteins in cells and inhibit DUB activity. Prosta-
glandin PGJ2 is a metabolite of PGD2 that is sequentially metabolized
toΔ12-PGJ2 or to 15Δ-PGJ2 (Fitzpatrick &Wynalda, 1983). PGJ2 prosta-
glandins contain α,β-unsaturated ketones that function as Michael ac-
ceptors (Fig. 9). Cyclopentenone PGs react with thiol molecules at the
β-position within the cyclopentenone ring (Suzuki et al., 1997). The
mechanism(s) of UPS inhibition by PGs may be complex. One study re-
ported that amajor intracellular target of protein carbonylationwas the
S6 ATPase of the 26S proteasome. Protein carbonylation and oxidative
stress induced by PGs decreased the activities of the S6 ATPase and
that of the proteasome (Ishii et al., 2005). Other investigators have re-
ported that cyclopentone PGs inhibit cellular DUB activities: UCHL3
was found to be inhibited by Δ12-PGJ2 (Li et al., 2004) and UCHL1 by
15Δ-PGJ2 (Liu et al., 2011c). 15Δ-PGJ2 affects UCHL1 overall structure,
resulting in inhibition of enzyme activity (Koharudin et al., 2010).
15Δ-PGJ2 has also been reported to stabilize p53, but p53 function
was functionally inactivated by binding of the PG to the Cys-277 residue
(Kim et al., 2010). Cysteine modiﬁcation sites of 15Δ-PGJ2 have been
identiﬁed in UCHL1 (Koharudin et al., 2010) and in Ras (Renedo et al.,
2007). Cyclopentenone PGs are known to induce apoptosis by mecha-
nisms that do not require the p53 pathway (Mullally et al., 2001). Oxi-
dative stress induced by 15Δ-PGJ2 was reported to be associated with
the formation of adducts between PG and thioredoxin 1 (Shibata et al.,
2003). Two cysteine residues in thioredoxin 1, Cys-35 and Cys-69,
were found to be modiﬁed by 15Δ-PGJ2. Interestingly, UCHL1 was re-
ported to be among the proteins that were oxidized in cells exposed
to 15Δ-PGJ2 (Ishii & Uchida, 2004) (Table 2).
The DUB inhibitory activity of cyclopentone PGs is very likely due to
the presence of Michael acceptors in these compounds and the fact that
the vast majority of DUBs are cysteine proteases. Among the amino acid
residues in proteins, cysteine is the most nucleophilic and reactive.
Whereas the pKa of free cysteine is 8.4, the pKa of a cysteine residue in
a protein is affected by the environment and varies between 4 and 9.
Basic residues close to cysteine sulfhydryls in the protein structure de-
crease the pKa of cysteine and result in ionization to cysteine thiolate
(RS−) at neutral pH. The nucleophilic nature of cysteine thiolate allows
it to react with Michael acceptors such as those present in maleimides,
vinyl sulfones, acrylamides, andα,β-unsaturated ketones and aldehydes.
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45P. D'Arcy et al. / Pharmacology & Therapeutics 147 (2015) 32–54Electrophiles differwith regard to their degree of reactivity to nucle-
ophiles based on the “hard/soft” acid–base principle (Lopachin et al.,
2012). α,β-Unsaturated ketones are considered as relatively soft elec-
trophiles and believed to be selective in their reaction to a subset ofTable 2
DUB inhibitors containing Michael acceptors.
Compound Reported activity
12Δ-PGJ2 UCHL3
15-Deoxy-Δ12,14-prostaglandin J2 UCHL1
G5 Inhibition of cellular Ub-A
F6 (NSC 632839) Inhibition of cellular Ub-A
USP2, USP7
SENP2 deSUMOylase
WP1130 USP5/USP9x/USP14/UCHL
b-AP15 USP14/UCHL5
AC17 USP14/UCHL5
AM146, RA-9 and RA-14 USP2a/USP2b/USP5/USP8
Eeyarestatin 1 Ataxin-3cysteine thiolates in proteins (Aldini et al., 2006). Proteomic studies
have shown that electrophiles react with “hyper-reactive” cysteines in
proteins (Weerapana et al., 2010; Codreanu et al., 2014). Acrolein (an
α,β-unsaturated aldehyde), glyoxal (a dialdehyde) and various keto-Ref
(Li et al., 2004; Lee et al., 2010)
(Liu et al., 2011)
MC cleavage (Aleo et al., 2006)
MC cleavage (Aleo et al., 2006; Nicholson et al., 2008)
1/UCHL5 (Kapuria et al., 2010)
(D'Arcy et al., 2011)
(Zhou et al., 2013)
(Issaenko and Amerik, 2012)
(Wang et al., 2008)
46 P. D'Arcy et al. / Pharmacology & Therapeutics 147 (2015) 32–54aldehydes are more reactive and cytotoxic compared to α,β-unsaturat-
ed ketones (Dalle-Donne et al., 2006). Acrolein reacts with guanine
bases in DNA, andwith cysteine, lysine, histidine, and arginine residues.
Punaglandins, chlorinated cyclopentenone PGs, are more potent in-
hibitors of cellular DUB activity than the J-series PGs (Verbitski et al.,
2004). The increased inhibitor activity was speculated to be due in-
creased reactivity towards the nucleophilic addition of the DUB catalytic
cysteine thiol group (Verbitski et al., 2004).
4.3. Chalcone DUB inhibitors
A chalcone is an aromatic ketone and an enone that forms the central
core for a variety of important biological compounds. A number of
chalcone compounds (e.g. G5, b-AP15, RA-9) have been described to in-
hibit cellular deubiquitinase activity (Fig. 9). These compounds are un-
related to PGs, but contain cross-conjugated α,β-unsaturated ketones
and accessibleβ-carbons, and generally inhibit DUB activity. These com-
pounds have been reported to be either relatively speciﬁc (b-AP15) or
broad spectrum (G5) DUB inhibitors. The reasons for these apparent
discrepancies are unknown.
Compounds G5 and F6 were identiﬁed in a cell based screen for Bcl-
2-independent apoptosis (Aleo et al., 2006). Both compounds are
chalcones that contain cross-conjugated α,β-unsaturated ketones.
These compounds were reported to inhibit total DUB activity (Aleo
et al., 2006) and F6 was reported to inhibit USP2 and USP7 and also
the SENP2 deSUMOylase (Nicholson et al., 2008). G5 induces apoptosis
at concentrations of ~1 μM, and necrotic cell death at higher concentra-
tions (10 μM) (Fontanini et al., 2009).
b-AP15 (Fig. 9)was identiﬁed in cell based screens for compounds in-
ducing apoptosis independently of p53 and cathepsin-D (Erdal et al.,
2005; Berndtsson et al., 2009) andwas found to induce the accumulation
of polyubiquitin in cells (Berndtsson et al., 2009). Subsequent work
showed that this compound blocks degradation of a proteasome-
degraded reporter protein, suggesting that DUB inhibition was linked
to a decrease in proteasome function (D'Arcy et al., 2011). b-AP15 in-
hibits the activity of proteasome associated cysteine DUBs (USP14 and
UCHL5) at concentrations of ~5 μM (D'Arcy et al., 2011; Wang et al., un-
published data) (Fig. 10). Dual inhibition of USP14 and UCHL5 using RNA
interference is known to lead to strong accumulation of proteasomal sub-
strates and loss of cell viability (Koulich et al., 2008; Tian et al., 2013;
Wang et al., 2014). Surprisingly, b-AP15 did not inhibit total cellular
DUB activity at concentrations of 20–50 μM (D'Arcy et al., 2011). Consid-
ering the structural similarity between b-AP15 and other chalcones,
these differences in speciﬁcity are surprising and are as of yet unex-
plained (see further below). b-AP15 shows considerable anti-neoplasticU
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Fig. 10. Inhibition of proteasomal DUBs impairs proteasome function and leads to the accumul
ported to show this mechanism of action (D'Arcy et al., 2011; Zhou et al., 2013).activity in animal models, both against solid tumors (D'Arcy et al.,
2011) and againstmultiplemyeloma (Tian et al., 2013). The cytotoxic ac-
tivity of the drug is strongly associated with functional proteasome inhi-
bition. Thus, monitoring accumulation of a proteasome-degraded
reporter (UbG76V-YFP) in cells exposed to low concentrations of b-AP15
showed a very strong correlation between blocking of proteasome activ-
ity and cell death (Brnjic et al., 2013;Wang et al., 2014). Importantly, ex-
amination of the cellular response to b-AP15 using gene expression
proﬁling and CMAP analysis (Lamb et al., 2006) showed that this com-
pound induced a very similar change in gene expression as a number
of proteasome inhibitors and to 15Δ-PGJ2 (D'Arcy et al., 2011).
AM146, RA-9, RA-14 and RAMB1 are all chalcones (RA-9 shown in
Fig. 9) (Anchoori et al., 2011; Issaenko & Amerik, 2012). These com-
pounds were described to act as partially selective DUB inhibitors and
to induce rapid accumulation of polyubiquitinated proteins and to de-
plete the cellular pools of free ubiquitin. AM146, RA-9, and RA-14
were found to inhibit UCHL1, UCHL3, USP2 and USP8, but did not sup-
press the activity of Ataxin-3, A20, BAP1, Otubain 1 or USP7 (Issaenko
& Amerik, 2012). These compounds elicit apoptosis of breast, ovarian
and cervical cancer cells but not of primary human cells.
4.4. Other DUB inhibitors containing Michael acceptors
WP1130 (degrasyn, Fig. 9) is a small-molecule compound that in-
hibits several DUBs of both USP and UCH subclasses, including USP9x,
USP5, USP14 and UCHL5 (Kapuria et al., 2010). In cells, the inhibition
of DUB activity resulted in the accumulation of polyubiquitinated conju-
gates. WP1130 induces the accumulation of free polyubiquitin chains,
presumably due to inhibition of USP5 (isopeptidase-T). Downregulation
of the anti-apoptotic protein MCL1 was observed in cells exposed to
WP1130. This effect is expected from the inhibition of USP9x, and is
not observed in cells exposed to b-AP15 (X.W., unpublished observa-
tion). Pham and colleagues showed that WP1130 in combination with
bortezomib had antitumor activity in a mantle cell lymphoma animal
model (Pham et al., 2010). In distinction to b-AP15, WP1130 was re-
ported not to induce oxidative stress (Kapuria et al., 2010). The inhibi-
tion of USP14 and UCHL5 by WP1130 is expected to induce a
functional block of proteasome function in cells, but this has not been
tested.
Eeyarestatin-1 (Eer1) (Fig. 9)was identiﬁed in a screen for inhibitors
of the ERAD pathway (Fiebiger et al., 2004). Subsequent studies have
shown that Eer1 inhibits p97/VCP-associated DUB activity, and that
ataxin-3 activity is inhibited by this compound (Wang et al., 2008).
Using surface plasmon resonance and pull-down assays, Eer1 has been
shown to directly bind to the p97 ATPase (261). Eer1 appears to haveb-AP15
AC17
U
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U
U
U
U
U
U
USP14UCHL5
ation of polyubiquitinated substrates in cells. Compounds b-AP15 and AC17 have been re-
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pound also inhibits anterograde translocation of proteins over the ER
(Cross et al., 2009; Aletrari et al., 2011). Eer1 has anti-cancer activities
resembling those of bortezomib (Wang et al., 2009).
4.5. Natural products with DUB inhibitory activity
A number of compounds have been described in the literature to af-
fect the UPS without direct inhibition of proteasome activity. Some of
these compounds have been reported to be DUB inhibitors.
Curcumin is a yellow pigment from the herb Curcuma longa present
in the Indian spice turmeric (associated with curry powder). Curcumin
is one of the most studied phytochemicals; in August 2014 a PubMed
search for “curcumin” and “cancer” resulted in 2579 hits (reviewed in
Shishodia et al. (2005)). Curcumin has been linked with suppression
of tumorigenesis as well as a number of other pathological conditions
and has been shown to be extremely safe even at very high doses.
Curcumin is a homodimer of feruloylmethane containing a methoxy
group and a hydroxyl group (Fig. 9). Importantly, curcumine contains
two α,β-unsaturated ketone moieties which are important for its anti-
cancer activity. Using a shotgun proteomic approach, it was found that
curcumin induces the accumulation of polyubiquitinated proteins at
concentrations of 40 μM (D'Aguanno et al., 2012). The ability of
curcumin to modulate molecular targets relevant to cancer, such as
NFκB, cyclin D1 and p21, may be speculated to be secondary to inhibi-
tion of the UPS (Shishodia et al., 2005) (Table 3).
The 4-arylidene curcumin analog AC17 (Fig. 9) has been shown to
inhibit the deubiquitinase activity of the 19S RP (Zhou et al., 2013)
(Fig. 10). AC17 inhibits NFκB activity and activates p53 in human lung
cancer cells and has anti-tumor activity in an in vivo model of human
lung cancer. AC17 was reported to be an irreversible inhibitor of 19S
DUB activity, presumably USP14/UCHL5 (Zhou et al., 2013). AC17 does
not inhibit total DUB activity in cell lysates (Zhou et al., 2013).
Betulinic acid is triterpene that has been isolated frommany diverse
plants, including the birch tree, Betula. Betulinic acid is cytotoxic against
a range of cancer cell lines, and shows signiﬁcant in vivo activity in
human melanoma xenograft animal models (Pisha et al., 1995). A 20%
betulinic acid ointment has been evaluated in the treatment of dysplas-
tic nevi (http://www.cancer.gov/drugdictionary?CdrID=496932).
Betulinic acid was recently reported to be a broad spectrum DUB inhib-
itor (Reiner et al., 2013). Betulinic acid has previously been used as a re-
agent in cancer research based on its ability to induce loss of
transmembrane potential in isolated mitochondria and to induce apo-
ptosis (Fulda et al., 1998).
Gambogic acid (GA) is a cytotoxic compound isolated from gam-
boge, a brownish resin of the tree Garcinia hanburyi in Southeast Asia.
This plant product has been used in Chinese traditional medicine for
centuries (Zhang et al., 2004; Chen et al., 2008). GA has been shown
to be an anticancer drug candidate with documented cytotoxic activity
in several types of cancer cells (Wu et al., 2004b; Reutrakul et al.,
2007; Yi et al., 2008). TheChinese Food andDrugAdministration has ap-
proved a phase II clinical trial of GA as an antitumor candidate (Qi et al.,
2008). GA has an α,β-unsaturated ketone structure which is essential
for growth inhibition and apoptosis induction in cancer cell lines
(Fig. 9) (Zhang et al., 2004; Reutrakul et al., 2007). The gene signature
observed in cells exposed to GA is similar to that of cells exposed to
UPS inhibitors such as PGJ2, celastrol and withaferin A (Felth et al.,Table 3
Natural products which are candidate DUB inhibitors.
Compound Reported activity
Curcumin Accumulation of polyubiquitin, contains α,β unsatu
AC17 (curcumin analog) USP14, UCH-L5
Betulinic acid Broad spectrum DUB inhibition
Gambogic acid Accumulation of polyubiquitin, contains α, β unsat2013). As expected from this result, GA induces the accumulation of
polyubiquitinated proteins. The presence of α,β-unsaturated ketones
suggested that GAmay inhibit cellular DUB activity, and thiswas indeed
found to be the case (Felth et al., 2013). The compound also inhibits 20S
proteasome activity (Felth et al., 2013).
4.6. Speciﬁcity of inhibitors containing α,β-unsaturated ketones
Michael acceptor-based inhibitors will achieve maximal selectivity
by targeting poorly conserved, noncatalytic cysteines (Singh et al.,
2011). Inhibitors with Michael acceptors that are believed to target cat-
alytic cysteines in DUBs nevertheless appear to show considerable spec-
iﬁcity. Some inhibitors such as b-AP15 and AC17were reported to show
speciﬁcity to proteasomal DUBs (D'Arcy et al., 2011; Zhou et al., 2013),
whereas others such as WP1130 showed a larger range of activities
but nevertheless some speciﬁcity (Kapuria et al., 2010). Some of these
differences may reﬂect different binding to target DUBs due to 3-D con-
formation of the inhibitors. However, it is surprising that G5/F6 is broad
speciﬁcity DUB inhibitors and b-AP15 is speciﬁc to proteasomal DUBs,
considering the similar molecular structures (i.e. chalcone) of these
drugs. b-AP15 has a low solubility in aqueous buffers, and it is conceiv-
able that b-AP15 would inhibit non-proteasomal DUBs if soluble at 10–
50 μM. However, analysis of myeloma cells exposed to 1 μM b-AP15
showed inhibition of USP14 in the same protein extracts where USP7,
UCHL3 or UCHL5 was not inhibited (Tian et al., 2013). Considering the
expected cytotoxicity resulting from blocking of proteasome function,
we believe it to be likely that the inhibition of proteasomal DUBs
(USP14/UCHL5) is of key importance to the biological effects of
chalcones and other α,β-unsaturated ketone-containing compounds.
Compounds containing α,β-unsaturated ketones frequently induce
cellular oxidative stress (Raj et al., 2011; Adams et al., 2012). Such com-
pounds have also been proposed to directly reactwith proteins, creating
“electrophilic stress” (Adams et al., 2012). Cyclopentone PGs, curcumin
and b-AP15 have all been found to inhibit thioredoxin reductase (Moos
et al., 2003; Fang et al., 2005; Wang et al., 2014) and 15Δ-PGJ2 binds
two cysteines in thioredoxin (Shibata et al., 2003). In the instance of
b-AP15, various pieces of evidence suggested that thioredoxin reduc-
tase inhibition contributes to oxidative stress by this compound but
does not appear essential for cytotoxicity (Wang et al., 2014). Induction
of an oxidative stress response is a general feature of proteasome inhib-
itors (including bortezomib and MG-262 (Ling et al., 2003; Wu et al.,
2002)), and may not necessarily require speciﬁc molecular sensors
such as Keap1–Nrf2 (Gao et al., 2007). When compared side-by-side,
b-AP15 and the thioredoxin reductase inhibitor auranoﬁn induce simi-
lar levels of oxidative stress, but only b-AP15 induces proteasome inhi-
bition (Wang et al., 2014).
Cysteine-dependent enzymes are not necessarily inhibited by α,β-
unsaturated ketone-containing compounds. Neither glutathione reduc-
tase nor caspase-3, enzymeswhichboth contain cysteines in their active
sites, are inhibited by b-AP15 (Wang et al., 2014) (X.W., unpublished in-
formation). PGJ2 induces a decline in proteasome activity and a shift in
the molecular make-up of proteasomes (decreases in 26S particles and
increases in 20S core particles) (Wang et al., 2006). b-AP15 does not in-
hibit proteasome activity (D'Arcy et al., 2011) and does not affect the as-
sembly of proteasomes in cells (M. Mazurkiewicz, unpublished data).
15Δ-PGJ2 has also been shown to covalently bind to a cysteine residue
in the PPARγ ligand (Shiraki et al., 2005) and to bind actin and otherrated ketones (Mullally and Fitzpatrick, 2002; D'Aguanno et al., 2012)
(Zhou et al., 2013)
(Reiner et al., 2013)
urated ketones (Felth et al., 2013)
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the actin ﬁlament network were observed using high concentrations
(20 μM) of 15Δ-PGJ2 (Aldini et al., 2007). Exposure of cells to 15Δ-
PGJ2 does not induce major shifts in the position of proteins found to
react with the PG on two-dimensional gels (Aldini et al., 2007), suggest-
ing that only a minor fraction of the protein was covalently modiﬁed.
With regard to the reactivity of dienones, see further below.
It is difﬁcult to deduce the molecular mechanism of action of 15Δ-
PGJ2, b-AP15 and other compounds using proteomic data since identi-
ﬁed targets are not necessarily associated with induction of apoptosis.
However, using CMAP analysis of induced gene expression proﬁles,
15Δ-PGJ2 and b-AP15 show proﬁles which are similar (but not identi-
cal) to those of 20S proteasome inhibitors (D'Arcy et al., 2011).
4.7. Pharmacological properties of
compounds containing α,β-unsaturated ketones
Curcumin is safe to humans at doses of 12 g/day but exhibits poor
bioavailability (Anand et al., 2007). Low plasma/tissue levels appear to
be mainly due to poor absorption and rapid metabolism. The anti-
tumor effects observed with orally administered curcumin in some
studies are somewhat surprising considering the limited bioavailability
of this compound. The use of piperine, an agent that interferes with
glucuronidation, has been reported to increase bioavailability (Shoba
et al., 1998; Anand et al., 2007).
An intriguing property of some of the inhibitors discussed here is
their stronger inhibitory effect in cellular assays compared to biochem-
ical in vitro assays. b-AP15 blocks proteasome activity in cellular assays
(accumulation of polyubiquitin and proteasome-degraded reporters) in
the 0.1–0.5 μM range, but inhibits proteasomal DUB activity in vitro at a
concentration of ~10 μM(Wang et al., 2014). This compoundwas found
to be rapidly taken up and enriched in cells (Wang et al., 2014),
explaining this apparent inconsistency. Enrichment appears to be
thiol-driven (Wang et al., 2014). Eer1 shows in vitro activity at
~70 μM in biochemical assays whereas 8 μM Eer1 is sufﬁcient to block
translocation of proteins over the ER in cultured cells (Cross et al.,
2009). This discrepancy was suggested to result from metabolism of
Eer1 in vivo (Wang et al., 2008). Cyclopentenone PGs have been found
to be enriched in cells by a factor of ~20-fold (Narumiya & Fukushima,
1986). Cellular enrichment of cyclopentenone PGs was reported to be
due to active transport over cell membranes (Narumiya & Fukushima,
1986).
4.8. Reactivity of α,β-dienones present in DUB inhibitors
Cysteine residues are ideal targets for covalent drugs with the po-
tential of target speciﬁcity and a prolonged residence time and, hence,
duration of action (Seraﬁmova et al., 2012). The BTK inhibitor ibrutinib
and the EGFR inhibitor afatinib represent examples of covalent kinase
inhibitors that target noncatalytic cysteine thiols (Liu et al., 2013;
Schwartz et al., 2014). Irreversible Michael acceptors such as acrylam-
ides may be converted to electrophiles that react with cysteine thiols
in a rapidly reversible fashion (Seraﬁmova et al., 2012). We have
found that the b-AP15 inhibitor induces reversible inhibition of
proteasome-associated DUB activity both in vitro (enzyme assays
using 26S proteasomes) or in vivo (determining the levels of
polyubiquitin after removal of drug) (D'Arcy et al., 2011; Wang et al.,
2014). Issaenko and Amerik (2012) reported that the chalcone AM146
elicited an irreversible commitment for cell death, suggesting that the
compound is an irreversible inhibitor. Whether DUB activity was irre-
versibly inhibited was not tested, however, and it is possible that com-
mitment to cell death was achieved even after short exposures to
AM146, as found using b-AP15 (Wang et al., 2014).
Addition of thiols such as glutathione to dienone PGs occurs more
rapidly but results in more labile thiol conjugates compared to enone
PGs (Suzuki et al., 1997). Interestingly, dienone reactivity is consideredto be under kinetic controlwhereas enone reactivity is under thermody-
namic control. Cross-conjugated dienone PGs undergo reversible
Michael addition reactions with glutathione, generating an equilibrium
mixture shifted to the free PG over the conjugated PG (Suzuki et al.,
1997). In contrast, enonePGs bindglutathione in an irreversiblemanner
so the equilibrium favors thiol conjugate formation. CDDO (2-cyano-3,
12-dioxooleana-1, 9-dien-28-oic acid) is a semi-synthetic triterpenoid
which contains two α,β-unsaturated carbonyls and is a promising che-
mopreventive and chemotherapeutic agent. CDDO has been demon-
strated to react with thiol nucleophiles, but nucleophilic addition is
both selective and reversible (Couch et al., 2005).
The pattern of reactivity of compounds containing α,β-unsaturated
carbonyls can be ﬁne-tuned bymanipulating their electronic properties
(Amslinger, 2010). Some of the differences in the speciﬁcity by these
compounds with regard to DUB inhibition could be envisioned to be
due to the varying strength of the electrophiles. Another important
issue is the potential general reactivity of these compounds, which
would seriously compromise the bioavailability of the drugs by non-
selective addition to scavengers such as glutathione, and could also be
envisioned to lead to general toxicity. However, most of the evidence
in the literature suggests that nucleophile addition to dienones is re-
versible and that a major fraction of various compounds are free to
bind various intracellular targets. It may nevertheless be advantageous
to attempt to develop prodrugswhere theα,β-unsaturated carbonyl re-
activity is activated in intracellular compartments.
5. Conclusions
Great efforts have been made to develop inhibitors of targets in the
UPS other than the proteasome. So far, however, no compounds have
been approved for clinical use. The potential to inﬂuence processes
such as signal transduction, proliferation and apoptosis by affecting
ubiquitination and proteasomal degradation of key regulators is both
promising and exciting. DUBs are likely to bemore druggable than E3 li-
gases owing to the lack of deﬁned catalytic residues in the latter. Most
DUBs are cysteine enzymes which should be easy to drug, particularly
using compounds containing Michael acceptors. The degree of speciﬁc-
ity which can be achieved by such compounds is uncertain. The overall
importance of DUBs for central cellular processes such as proper
proteasomal function may explain the cytotoxic proﬁles of interesting
natural products such as curcumin and synthetic chalcones. Bioavail-
ability is a hurdle that needs to be overcome, but if progress can be
made in this area molecules containing functional dienones as well as
other types of compounds may be developed into useful cancer
therapeutics.
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